BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bergasa NV, Schmitt JM, Talbot TL, Alling DW, Swain MG, Turner ML, Jenkins JB, Jones EA. Open-label trial of oral nalmefene therapy for the pruritus of cholestasis. Hepatology. 1998;27:679-684. [PMID: 9500694 DOI: 10.1002/hep.510270307] [Cited by in Crossref: 127] [Cited by in F6Publishing: 102] [Article Influence: 5.3] [Reference Citation Analysis]
Number Citing Articles
1 Bergasa NV. Lysophosphatidic acid and atotaxin in patients with cholestasis and pruritus: Fine biology, anticipated discernment. Annals of Hepatology 2010;9:475-9. [DOI: 10.1016/s1665-2681(19)31629-1] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
2 Bergasa NV. The pruritus of cholestasis: From bile acids to opiate agonists: Relevant after all these years. Medical Hypotheses 2018;110:86-9. [DOI: 10.1016/j.mehy.2017.11.002] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
3 Schäkel K, Döbel T, Bosselmann I. Future treatment options for atopic dermatitis – Small molecules and beyond. Journal of Dermatological Science 2014;73:91-100. [DOI: 10.1016/j.jdermsci.2013.11.009] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
4 Umeuchi H, Togashi Y, Honda T, Nakao K, Okano K, Tanaka T, Nagase H. Involvement of central mu-opioid system in the scratching behavior in mice, and the suppression of it by the activation of kappa-opioid system. Eur J Pharmacol. 2003;477:29-35. [PMID: 14512095 DOI: 10.1016/j.ejphar.2003.08.007] [Cited by in Crossref: 99] [Cited by in F6Publishing: 76] [Article Influence: 5.5] [Reference Citation Analysis]
5 Meixiong J, Vasavda C, Green D, Zheng Q, Qi L, Kwatra SG, Hamilton JP, Snyder SH, Dong X. Identification of a bilirubin receptor that may mediate a component of cholestatic itch. Elife 2019;8:e44116. [PMID: 30657454 DOI: 10.7554/eLife.44116] [Cited by in Crossref: 38] [Cited by in F6Publishing: 17] [Article Influence: 12.7] [Reference Citation Analysis]
6 Marzioni M, Svegliati Baroni G, Alpini G, Benedetti A. Endogenous opioid peptides and chronic liver disease: from bedside to bench. J Hepatol 2007;46:583-6. [PMID: 17313989 DOI: 10.1016/j.jhep.2007.01.006] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
7 Ho V, Stewart M, Boyd P. Cholestatic hepatitis as a possible new side-effect of oxycodone: a case report. J Med Case Rep 2008;2:140. [PMID: 18452597 DOI: 10.1186/1752-1947-2-140] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
8 Tajiri K, Shimizu Y. Recent advances in the management of pruritus in chronic liver diseases. World J Gastroenterol 2017; 23(19): 3418-3426 [PMID: 28596678 DOI: 10.3748/wjg.v23.i19.3418] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
9 Bergasa NV, Link MJ, Keogh M, Yaroslavsky G, Rosenthal RN, Mcgee M. Pilot Study of Bright-Light Therapy Reflected Toward the Eyes for the Pruritus of Chronic Liver Disease. American Journal of Gastroenterology 2001;96:1563-70. [DOI: 10.1111/j.1572-0241.2001.03778.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 25] [Article Influence: 1.7] [Reference Citation Analysis]
10 Pauli-magnus C, Mikus G, Alscher DM, Kirschner T, Nagel W, Gugeler N, Risler T, Berger ED, Kuhlmann U, Mettang T. Naltrexone Does Not Relieve Uremic Pruritus: Results of a Randomized, Double-Blind, Placebo-Controlled Crossover Study. JASN 2000;11:514-9. [DOI: 10.1681/asn.v113514] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 1.8] [Reference Citation Analysis]
11 Jones EA, Bergasa NV. The pruritus of cholestasis. Hepatology. 1999;29:1003-1006. [PMID: 10094938 DOI: 10.1002/hep.510290450] [Cited by in Crossref: 117] [Cited by in F6Publishing: 91] [Article Influence: 5.1] [Reference Citation Analysis]
12 Yosipovitch G. Pruritus. Current Problems in Dermatology 2003;15:143-64. [DOI: 10.1016/s1040-0486(03)00017-6] [Cited by in Crossref: 14] [Article Influence: 0.7] [Reference Citation Analysis]
13 Trivedi HD, Lizaola B, Tapper EB, Bonder A. Management of Pruritus in Primary Biliary Cholangitis: A Narrative Review. The American Journal of Medicine 2017;130:744.e1-7. [DOI: 10.1016/j.amjmed.2017.01.037] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.6] [Reference Citation Analysis]
14 Trauner M, Boyer JL. Cholestatic syndromes: . Current Opinion in Gastroenterology 1999;15:217-28. [DOI: 10.1097/00001574-199905000-00006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
15 Glasova H, Beuers U. Extrahepatic manifestations of cholestasis. Journal of Gastroenterology and Hepatology 2002;17:938-48. [DOI: 10.1046/j.1440-1746.2002.02717.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
16 Davis M. Cholestasis and endogenous opioids: liver disease and exogenous opioid pharmacokinetics. Clin Pharmacokinet 2007;46:825-50. [PMID: 17854233 DOI: 10.2165/00003088-200746100-00002] [Cited by in Crossref: 33] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
17 Parés A, Cisneros L, Salmerón JM, Caballería L, Mas A, Torras A, Rodés J. Extracorporeal albumin dialysis: a procedure for prolonged relief of intractable pruritus in patients with primary biliary cirrhosis. Am J Gastroenterol. 2004;99:1105-1110. [PMID: 15180733 DOI: 10.1111/j.1572-0241.2004.30204.x] [Cited by in Crossref: 77] [Cited by in F6Publishing: 62] [Article Influence: 4.3] [Reference Citation Analysis]
18 Hope AA, Morrison RS. Integrating Palliative Care with Chronic Liver Disease Care. J Palliat Care 2011;27:20-7. [DOI: 10.1177/082585971102700105] [Cited by in Crossref: 18] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
19 Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ; American Association for Study of Liver Diseases. Primary biliary cirrhosis. Hepatology. 2009;50:291-308. [PMID: 19554543 DOI: 10.1002/hep.22906] [Cited by in Crossref: 850] [Cited by in F6Publishing: 705] [Article Influence: 65.4] [Reference Citation Analysis]
20 Bergasa N, Liau S, Homel P, Ghali V. Hepatic Met-enkephalin immunoreactivity is enhanced in primary biliary cirrhosis: Met-enkephalin in PBC livers. Liver 2002;22:107-13. [DOI: 10.1034/j.1600-0676.2002.01458.x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 46] [Article Influence: 3.8] [Reference Citation Analysis]
21 Paumgartner G, Pusl T. Medical treatment of cholestatic liver disease. Clin Liver Dis. 2008;12:53-80, viii. [PMID: 18242497 DOI: 10.1016/j.cld.2007.11.013] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 2.1] [Reference Citation Analysis]
22 Bergasa NV, McGee M, Ginsburg IH, Engler D. Gabapentin in patients with the pruritus of cholestasis: a double-blind, randomized, placebo-controlled trial. Hepatology. 2006;44:1317-1323. [PMID: 17058231 DOI: 10.1002/hep.21370] [Cited by in Crossref: 69] [Cited by in F6Publishing: 45] [Article Influence: 4.3] [Reference Citation Analysis]
23 Terán A, Fábrega E, Pons-Romero F. [Pruritus associated with cholestasis]. Gastroenterol Hepatol 2010;33:313-22. [PMID: 19836105 DOI: 10.1016/j.gastrohep.2009.07.006] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
24 McRae CA, Prince MI, Hudson M, Day CP, James OF, Jones DE. Pain as a complication of use of opiate antagonists for symptom control in cholestasis. Gastroenterology 2003;125:591-6. [PMID: 12891561 DOI: 10.1016/s0016-5085(03)00879-5] [Cited by in Crossref: 55] [Cited by in F6Publishing: 10] [Article Influence: 2.9] [Reference Citation Analysis]
25 Sanchez W, Talwalkar JA. Palliative care for patients with end-stage liver disease ineligible for liver transplantation. Gastroenterol Clin North Am 2006;35:201-19. [PMID: 16530121 DOI: 10.1016/j.gtc.2005.12.007] [Cited by in Crossref: 40] [Cited by in F6Publishing: 31] [Article Influence: 2.5] [Reference Citation Analysis]
26 Summey BT, Yosipovitch G. Pharmacologic advances in the systemic treatment of itch. Dermatol Ther 2005;18:328-32. [DOI: 10.1111/j.1529-8019.2005.00035.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 2.4] [Reference Citation Analysis]
27 Grundmann SA, Ständer S. Evaluation of chronic pruritus in older patients. Aging Health 2010;6:53-66. [DOI: 10.2217/ahe.09.84] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
28 Kunzmann S, Kullak-ublick GA, Greiner A, Jeschke R, Hebestreit H. Effective Opiate-Receptor Antagonist Therapy of Cholestatic Pruritus Induced by an Oral Contraceptive: . Journal of Pediatric Gastroenterology and Nutrition 2005;40:596-9. [DOI: 10.1097/01.mpg.0000148775.64966.96] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
29 Angulo P, Lindor KD. PRIMARY BILIARY CIRRHOSIS AND PRIMARY SCLEROSING CHOLANGITIS. Clinics in Liver Disease 1999;3:529-70. [DOI: 10.1016/s1089-3261(05)70084-2] [Cited by in Crossref: 25] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
30 Mccain JD, Chascsa DM, Lindor KD. Assessing and managing symptom burden and quality of life in primary sclerosing cholangitis patients. Expert Opinion on Orphan Drugs 2021;9:53-66. [DOI: 10.1080/21678707.2021.1898370] [Reference Citation Analysis]
31 Hohenester S, Oude-Elferink RP, Beuers U. Primary biliary cirrhosis. Semin Immunopathol. 2009;31:283-307. [PMID: 19603170 DOI: 10.1007/s00281-009-0164-5] [Cited by in Crossref: 114] [Cited by in F6Publishing: 96] [Article Influence: 8.8] [Reference Citation Analysis]
32 Zellos A, Roy A, Schwarz KB. Use of oral naltrexone for severe pruritus due to cholestatic liver disease in children. J Pediatr Gastroenterol Nutr 2010;51:787-9. [PMID: 20948447 DOI: 10.1097/MPG.0b013e3181eb5ac0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 2] [Article Influence: 1.6] [Reference Citation Analysis]
33 Steinhoff M, Cevikbas F, Ikoma A, Berger TG. Pruritus: management algorithms and experimental therapies. Semin Cutan Med Surg 2011;30:127-37. [PMID: 21767775 DOI: 10.1016/j.sder.2011.05.001] [Cited by in Crossref: 40] [Cited by in F6Publishing: 27] [Article Influence: 3.6] [Reference Citation Analysis]
34 Gossard AA, Lindor KD. Current and promising therapy for primary biliary cholangitis. Expert Opinion on Pharmacotherapy 2019;20:1161-7. [DOI: 10.1080/14656566.2019.1601701] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
35 Pusl T, Beuers U. Extrahepatic manifestations of cholestatic liver diseases: pathogenesis and therapy. Clin Rev Allergy Immunol. 2005;28:147-157. [PMID: 15879620 DOI: 10.1385/criai:28:2:147] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
36 Franco J. Pruritus. Curr Treat Options Gastro 1999;2:451-6. [DOI: 10.1007/s11938-999-0048-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.4] [Reference Citation Analysis]
37 Bergasa NV, Jones EA. Assessment of the Visual Analogue Score in the Evaluation of the Pruritus of Cholestasis. J Clin Transl Hepatol 2017;5:203-7. [PMID: 28936401 DOI: 10.14218/JCTH.2017.00001] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
38 Nicoll J, Axiotis CA, Bergasa NV. The delta opioid receptor 1 is expressed by proliferating bile ductules in rats with cholestasis: implications for the study of liver regeneration and malignant transformation of biliary epithelium. Med Hypotheses. 2005;65:1099-1105. [PMID: 16125331 DOI: 10.1016/j.mehy.2005.06.019] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
39 Gingold AR, Bergasa NV. The cannabinoid agonist WIN 55, 212-2 increases nociception threshold in cholestatic rats: implications for the treatment of the pruritus of cholestasis. Life Sciences 2003;73:2741-7. [DOI: 10.1016/s0024-3205(03)00668-4] [Cited by in Crossref: 33] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
40 Jones EA. Personal view: a potential novel treatment for fatigue complicating chronic liver disease - how should its efficacy be evaluated? Aliment Pharmacol Ther 2006;23:1113-6. [DOI: 10.1111/j.1365-2036.2006.02862.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
41 Selmi C, Meroni PL, Gershwin ME. Primary biliary cirrhosis and Sjögren’s syndrome: autoimmune epithelitis. J Autoimmun. 2012;39:34-42. [PMID: 22178199 DOI: 10.1016/j.jaut.2011.11.005] [Cited by in Crossref: 79] [Cited by in F6Publishing: 68] [Article Influence: 7.2] [Reference Citation Analysis]
42 Bergasa NV, Zhou J, Ravi J, Shi Q. The opioid peptide analog d-Ala2-Met-enkephalinamide decreases bile flow by a central mechanism☆. Peptides 1999;20:979-86. [DOI: 10.1016/s0196-9781(99)00091-1] [Cited by in Crossref: 9] [Article Influence: 0.4] [Reference Citation Analysis]
43 Selmi C, Bowlus CL, Gershwin ME, Coppel RL. Primary biliary cirrhosis. Lancet. 2011;377:1600-1609. [PMID: 21529926 DOI: 10.1016/s0140-6736(10)61965-4] [Cited by in Crossref: 193] [Cited by in F6Publishing: 85] [Article Influence: 17.5] [Reference Citation Analysis]
44 Brune A, Metze D, Luger TA, Ständer S. [Antipruritic therapy with the oral opioid receptor antagonist naltrexone. Open, non-placebo controlled administration in 133 patients]. Hautarzt 2004;55:1130-6. [PMID: 15517116 DOI: 10.1007/s00105-004-0802-8] [Cited by in Crossref: 35] [Cited by in F6Publishing: 27] [Article Influence: 2.1] [Reference Citation Analysis]
45 Homayoun H, Sayyah M, Dehpour AR. The additive effect of opioids and nitric oxide in increasing pentylenetetrazole-induced seizure threshold in cholestatic mice. J Gastroenterol Hepatol 2002;17:96-101. [DOI: 10.1046/j.1440-1746.2002.02658.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 0.9] [Reference Citation Analysis]
46 Bergasa NV. Medical palliation of the jaundiced patient with pruritus. Gastroenterol Clin North Am. 2006;35:113-123. [PMID: 16530114 DOI: 10.1016/j.gtc.2005.12.008] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
47 Chang Y, Golkar L. The Use of Naltrexone in the Management of Severe Generalized Pruritus in Biliary Atresia: Report of a Case. Pediatr Dermatol 2008;25:403-4. [DOI: 10.1111/j.1525-1470.2008.00699.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
48 Bergasa NV. Update on the Treatment of the Pruritus of Cholestasis. Clinics in Liver Disease 2008;12:219-34. [DOI: 10.1016/j.cld.2007.11.009] [Cited by in Crossref: 23] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
49 Tandon P, Rowe BH, Vandermeer B, Bain VG. The Efficacy and Safety of Bile Acid Binding Agents, Opioid Antagonists, or Rifampin in the Treatment of Cholestasis-Associated Pruritus. Am J Gastroenterology 2007;102:1528-36. [DOI: 10.1111/j.1572-0241.2007.01200.x] [Cited by in Crossref: 113] [Cited by in F6Publishing: 76] [Article Influence: 7.5] [Reference Citation Analysis]
50 Kremer AE, Feramisco J, Reeh PW, Beuers U, Oude Elferink RP. Receptors, cells and circuits involved in pruritus of systemic disorders. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2014;1842:869-92. [DOI: 10.1016/j.bbadis.2014.02.007] [Cited by in Crossref: 58] [Cited by in F6Publishing: 47] [Article Influence: 7.3] [Reference Citation Analysis]
51 Levy C, Lindor KD. Current management of primary biliary cirrhosis and primary sclerosing cholangitis. J Hepatol. 2003;38 Suppl 1:S24-S37. [PMID: 12591184 DOI: 10.1016/s0168-8278(03)00006-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
52 Shawcross DL, Jalan R. Delayed opioid withdrawal-like reaction in primary biliary cirrhosis following naloxone therapy. Gastroenterology 2001;121:743-4. [PMID: 11547785 DOI: 10.1053/gast.2001.27714] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.4] [Reference Citation Analysis]
53 Rost D, Kulaksiz H, Stiehl A. Treatment of primary sclerosing cholangitis. Curr Treat Options Gastro 2007;10:111-9. [DOI: 10.1007/s11938-007-0063-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
54 Ibrahim SH, Lindor KD. Current Management of Primary Sclerosing Cholangitis in Pediatric Patients: . Pediatric Drugs 2011;13:87-95. [DOI: 10.2165/11586500-000000000-00000] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
55 Bergasa NV. Pruritus in primary biliary cirrhosis: pathogenesis and therapy. Clin Liver Dis. 2008;12:385-406; x. [PMID: 18456187 DOI: 10.1016/j.cld.2008.02.013] [Cited by in Crossref: 40] [Cited by in F6Publishing: 30] [Article Influence: 2.9] [Reference Citation Analysis]
56 Kremer AE, Oude Elferink RP, Beuers U. Pathophysiology and current management of pruritus in liver disease. Clin Res Hepatol Gastroenterol. 2011;35:89-97. [PMID: 21809485 DOI: 10.1016/j.clinre.2010.10.007] [Cited by in Crossref: 66] [Cited by in F6Publishing: 57] [Article Influence: 6.0] [Reference Citation Analysis]
57 Metze D, Reimann S, Beissert S, Luger T. Efficacy and safety of naltrexone, an oral opiate receptor antagonist, in the treatment of pruritus in internal and dermatological diseases. Journal of the American Academy of Dermatology 1999;41:533-9. [DOI: 10.1016/s0190-9622(99)80048-6] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
58 Hong J, Buddenkotte J, Berger TG, Steinhoff M. Management of itch in atopic dermatitis. Semin Cutan Med Surg. 2011;30:71-86. [PMID: 21767767 DOI: 10.1016/j.sder.2011.05.002] [Cited by in Crossref: 79] [Cited by in F6Publishing: 67] [Article Influence: 7.2] [Reference Citation Analysis]
59 Millington G, Collins A, Lovell C, Leslie T, Yong A, Morgan J, Ajithkumar T, Andrews M, Rushbook S, Coelho R, Catten S, Lee K, Skellett A, Affleck A, Exton L, Mohd Mustapa M, Levell N, Mchenry P, Gibbon K, Buckley D, Leslie T, Mallon E, Wakelin S, Ungureanu S, Hunasehally R, Cork M, Johnston G, Chiang N, Natkunarajah J, Worsnop F, Duarte Williamson C, Donnelly J, Towers K, Saunders C, Adbi Salad A, Brain A. British Association of Dermatologists’ guidelines for the investigation and management of generalized pruritus in adults without an underlying dermatosis, 2018. Br J Dermatol 2018;178:34-60. [DOI: 10.1111/bjd.16117] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 9.3] [Reference Citation Analysis]
60 Soeberdt M, Kilic A, Abels C. Current and emerging treatments targeting the neuroendocrine system for disorders of the skin and its appendages. Exp Dermatol 2020;29:801-13. [DOI: 10.1111/exd.14145] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
61 Nunes ACR, Amaro P, Maçôas F, Cipriano A, Martins I, Rosa A, Pimenta I, Donato A, Freitas D. Fosinopril-induced prolonged cholestatic jaundice and pruritus: first case report: . European Journal of Gastroenterology & Hepatology 2001;13:279-82. [DOI: 10.1097/00042737-200103000-00011] [Cited by in Crossref: 31] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
62 Pusl T, Beuers U. Extrahepatic manifestations of cholestatic liver diseases: pathogenesis and therapy. Clin Rev Allergy Immunol. 2005;28:147-157. [PMID: 15879620 DOI: 10.1385/criai:] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
63 Ng VL, Ryckman FC, Porta G, Miura IK, de Carvalho E, Servidoni MF, Bezerra JA, Balistreri WF. Long-term Outcome After Partial External Biliary Diversion for Intractable Pruritus in Patients With Intrahepatic Cholestasis: . Journal of Pediatric Gastroenterology and Nutrition 2000;30:152-6. [DOI: 10.1097/00005176-200002000-00011] [Cited by in Crossref: 65] [Cited by in F6Publishing: 56] [Article Influence: 3.0] [Reference Citation Analysis]
64 Mezey E, Burns C, Burdick JF, Braine HG. A case of severe benign intrahepatic cholestasis treated with liver transplantation. Am J Gastroenterology 2002;97:475-7. [DOI: 10.1111/j.1572-0241.2002.05458.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
65 Bergasa NV, Alling DW, Talbot TL, Wells MC, Jones E. Oral nalmefene therapy reduces scratching activity due to the pruritus of cholestasis: A controlled study. Journal of the American Academy of Dermatology 1999;41:431-4. [DOI: 10.1016/s0190-9622(99)70117-9] [Cited by in Crossref: 117] [Cited by in F6Publishing: 12] [Article Influence: 5.1] [Reference Citation Analysis]
66 Villamil AG, Bandi JC, Galdame OA, Gerona S, Gadano AC. Efficacy of lidocaine in the treatment of pruritus in patients with chronic cholestatic liver diseases. Am J Med. 2005;118:1160-1163. [PMID: 16194649 DOI: 10.1016/j.amjmed.2005.05.031] [Cited by in Crossref: 34] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
67 Neuberger J, Jones EA. Liver transplantation for intractable pruritus is contraindicated before an adequate trial of opiate antagonist therapy. Eur J Gastroenterol Hepatol. 2001;13:1393-1394. [PMID: 11692070 DOI: 10.1097/00042737-200111000-00022] [Cited by in Crossref: 41] [Cited by in F6Publishing: 33] [Article Influence: 2.1] [Reference Citation Analysis]
68 Sherlock S. Primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune cholangitis. Clin Liver Dis 2000;4:97-113. [PMID: 11232193 DOI: 10.1016/s1089-3261(05)70098-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
69 Talwalkar JA, Lindor KD. Primary biliary cirrhosis. Lancet. 2003;362:53-61. [PMID: 12853201 DOI: 10.1016/s0140-6736(03)13808-1] [Cited by in Crossref: 230] [Cited by in F6Publishing: 61] [Article Influence: 12.1] [Reference Citation Analysis]
70 Vaccarino AL, Olson GA, Olson RD, Kastin AJ. Endogenous opiates: 1998. Peptides 1999;20:1527-74. [PMID: 10698131 DOI: 10.1016/s0196-9781(99)00166-7] [Cited by in Crossref: 69] [Cited by in F6Publishing: 11] [Article Influence: 3.1] [Reference Citation Analysis]
71 Levy C, Lindor KD. Management of primary biliary cirrhosis. Curr Treat Options Gastro 2003;6:493-8. [DOI: 10.1007/s11938-003-0051-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
72 Bergasa NV, Mehlman JK, Jones EA. Pruritus and fatigue in primary biliary cirrhosis. Baillieres Best Pract Res Clin Gastroenterol. 2000;14:643-655. [PMID: 10976020 DOI: 10.1053/bega.2000.0109] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 2.0] [Reference Citation Analysis]
73 Carrion AF, Rosen JD, Levy C. Understanding and Treating Pruritus in Primary Biliary Cholangitis. Clinics in Liver Disease 2018;22:517-32. [DOI: 10.1016/j.cld.2018.03.005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
74 Lonsdale-eccles A, Carmichael AJ. Treatment of Pruritus Associated with Systemic Disorders in the Elderly: A Review of the Role of New Therapies. Drugs & Aging 2003;20:197-208. [DOI: 10.2165/00002512-200320030-00004] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
75 Leung KK, Deeb M, Hirschfield GM. Review article: pathophysiology and management of primary biliary cholangitis. Aliment Pharmacol Ther. [DOI: 10.1111/apt.16023] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
76 Wakasa Y, Fujiwara A, Umeuchi H, Endoh T, Okano K, Tanaka T, Nagase H. Inhibitory effects of TRK-820 on systemic skin scratching induced by morphine in rhesus monkeys. Life Sciences 2004;75:2947-57. [DOI: 10.1016/j.lfs.2004.05.033] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 1.6] [Reference Citation Analysis]
77 Mela M, Mancuso A, Burroughs AK. Review article: pruritus in cholestatic and other liver diseases. Aliment Pharmacol Ther. 2003;17:857-870. [PMID: 12656688 DOI: 10.1046/j.1365-2036.2003.01458.x] [Cited by in Crossref: 89] [Cited by in F6Publishing: 64] [Article Influence: 4.7] [Reference Citation Analysis]
78 Terg R, Coronel E, Sordá J, Muñoz AE, Findor J. Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study. J Hepatol 2002;37:717-22. [PMID: 12445410 DOI: 10.1016/s0168-8278(02)00318-5] [Cited by in Crossref: 113] [Cited by in F6Publishing: 22] [Article Influence: 5.9] [Reference Citation Analysis]
79 Phan NQ, Bernhard JD, Luger TA, Ständer S. Antipruritic treatment with systemic μ-opioid receptor antagonists: a review. J Am Acad Dermatol. 2010;63:680-688. [PMID: 20462660 DOI: 10.1016/j.jaad.2009.08.052] [Cited by in Crossref: 109] [Cited by in F6Publishing: 77] [Article Influence: 9.1] [Reference Citation Analysis]
80 Choi YS, Billings J. Opioid Antagonists. Journal of Pain and Symptom Management 2002;24:71-90. [DOI: 10.1016/s0885-3924(02)00424-4] [Cited by in Crossref: 105] [Cited by in F6Publishing: 26] [Article Influence: 5.3] [Reference Citation Analysis]
81 Mettang T. Chronic Kidney Disease-Associated Pruritus. In: Misery L, Ständer S, editors. Pruritus. London: Springer; 2010. pp. 166-75. [DOI: 10.1007/978-1-84882-322-8_27] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
82 Jones EA, Dekker LR. Florid opioid withdrawal-like reaction precipitated by naltrexone in a patient with chronic cholestasis. Gastroenterology 2000;118:431-2. [PMID: 10648471 DOI: 10.1016/s0016-5085(00)70225-3] [Cited by in Crossref: 53] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
83 Cherny NI. Taking care of the terminally ill cancer patient: management of gastrointestinal symptoms in patients with advanced cancer. Ann Oncol 2004;15 Suppl 4:iv205-13. [PMID: 15477309 DOI: 10.1093/annonc/mdh928] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
84 Bergasa NV. Pruritus in chronic liver disease: mechanisms and treatment. Curr Gastroenterol Rep 2004;6:10-6. [PMID: 14720448 DOI: 10.1007/s11894-004-0020-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
85 Mansour-Ghanaei F, Taheri A, Froutan H, Ghofrani H, Nasiri-Toosi M, Bagherzadeh AH, Farahvash MJ, Mirmomen S, Ebrahimi-Dariani N, Farhangi E, Pourrasouli Z. Effect of oral naltrexone on pruritus in cholestatic patients. World J Gastroenterol 2006; 12(7): 1125-1128 [PMID: 16534857 DOI: 10.3748/wjg.v12.i7.1125] [Cited by in CrossRef: 49] [Cited by in F6Publishing: 37] [Article Influence: 3.1] [Reference Citation Analysis]
86 Lisboa LF, Asthana S, Kremer A, Swain M, Bagshaw SM, Gibney N, Karvellas CJ. Blood cytokine, chemokine and gene expression in cholestasis patients with intractable pruritis treated with a molecular adsorbent recirculating system: a case series. Can J Gastroenterol 2012;26:799-805. [PMID: 23166903 DOI: 10.1155/2012/623862] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
87 Saab S, Han S, Martin P. LIVER TRANSPLANTATION. Clinics in Liver Disease 2000;4:513-32. [DOI: 10.1016/s1089-3261(05)70124-0] [Cited by in Crossref: 8] [Article Influence: 0.4] [Reference Citation Analysis]
88 Kremer AE, Beuers U, Oude-Elferink RP, Pusl T. Pathogenesis and treatment of pruritus in cholestasis. Drugs. 2008;68:2163-2182. [PMID: 18840005 DOI: 10.2165/00003495-200868150-00006] [Cited by in Crossref: 77] [Cited by in F6Publishing: 58] [Article Influence: 5.9] [Reference Citation Analysis]
89 Crosignani A, Battezzati PM, Invernizzi P, Selmi C, Prina E, Podda M. Clinical features and management of primary biliary cirrhosis. World J Gastroenterol 2008; 14(21): 3313-3327 [PMID: 18528929 DOI: 10.3748/wjg.14.3313] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 25] [Article Influence: 2.2] [Reference Citation Analysis]
90 Bunchorntavakul C, Reddy KR. Pruritus in chronic cholestatic liver disease. Clin Liver Dis 2012;16:331-46. [PMID: 22541702 DOI: 10.1016/j.cld.2012.03.010] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 3.5] [Reference Citation Analysis]
91 Bergasa NV. The pruritus of cholestasis. J Hepatol. 2005;43:1078-1088. [PMID: 16253381 DOI: 10.1016/j.jhep.2005.09.004] [Cited by in Crossref: 82] [Cited by in F6Publishing: 58] [Article Influence: 4.8] [Reference Citation Analysis]
92 Bergasa NV. Studying pruritus in the 21st century. Clinical Gastroenterology and Hepatology 2003;1:249-51. [DOI: 10.1016/s1542-3565(03)00140-x] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
93 Narkewicz MR. Biliary atresia: an update on our understanding of the disorder. Curr Opin Pediatr 2001;13:435-40. [PMID: 11801889 DOI: 10.1097/00008480-200110000-00009] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
94 Prince MI, Burt AD, Jones DE. Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis. Gut. 2002;50:436-439. [PMID: 11839728 DOI: 10.1136/gut.50.3.436] [Cited by in Crossref: 140] [Cited by in F6Publishing: 111] [Article Influence: 7.0] [Reference Citation Analysis]
95 Bergasa NV. Pruritus and fatigue in primary biliary cirrhosis. Clin Liver Dis. 2003;7:879-900. [PMID: 14594135 DOI: 10.1016/s1089-3261(03)00105-3] [Cited by in Crossref: 33] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
96 Jones E. Trials of opiate antagonists for the pruritus of cholestasis: primary efficacy endpoints and opioid withdrawal-like reactions. Journal of Hepatology 2002;37:863-5. [DOI: 10.1016/s0168-8278(02)00347-1] [Cited by in Crossref: 11] [Article Influence: 0.6] [Reference Citation Analysis]
97 Mani AR, Rasool R, Montagnese S, Dehpour AR. Endogenous opioids and liver disease. Scandinavian Journal of Gastroenterology 2009;41:1-11. [DOI: 10.1080/00365520500287533] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
98 Barnett V, Twycross R, Mihalyo M, Wilcock A. Opioid Antagonists. Journal of Pain and Symptom Management 2014;47:341-52. [DOI: 10.1016/j.jpainsymman.2013.12.223] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
99 Jones E, Zylicz Z. Treatment of Pruritus Caused by Cholestasis with Opioid Antagonists. Journal of Palliative Medicine 2005;8:1290-4. [DOI: 10.1089/jpm.2005.8.1290] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
100 Cotes ME, Swerlick RA. Practical guidelines for the use of steroid-sparing agents in the treatment of chronic pruritus. Dermatol Ther 2013;26:120-34. [PMID: 23551369 DOI: 10.1111/dth.12026] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
101 Zylicz Z, Krajnik M. Codeine for pruritus in primary billiary cirrhosis. The Lancet 1999;353:813. [DOI: 10.1016/s0140-6736(99)00259-7] [Cited by in Crossref: 14] [Article Influence: 0.6] [Reference Citation Analysis]
102 Shafaroodi H, Ghasemi M, Dehpour AR. Elevation of pentylenetetrazole-induced seizure threshold in cholestatic mice: Interaction between opioid and cannabinoid systems. Journal of Gastroenterology and Hepatology 2008;23:e251-7. [DOI: 10.1111/j.1440-1746.2007.05101.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
103 Bergasa NV. An approach to the management of the pruritus of cholestasis. Clinics in Liver Disease 2004;8:55-66. [DOI: 10.1016/s1089-3261(03)00128-4] [Cited by in Crossref: 9] [Article Influence: 0.5] [Reference Citation Analysis]
104 Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M. Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases. Hepatology. 2019;69:394-419. [PMID: 30070375 DOI: 10.1002/hep.30145] [Cited by in Crossref: 86] [Cited by in F6Publishing: 92] [Article Influence: 21.5] [Reference Citation Analysis]